A common diabetes medication could be used as treatment for patients with heart failure
At the European Society of Cardiology Congress 2019, Professor John McMurray presented results from the DAPA-HF trial proving that the diabetes drug, Dapagliflozin, could be used as treatment for patients with heart failure, even if they do not also have diabetes.
The common diabetes medication, originally introduced as a treatment for diabetes, can be successfully used to treat patients with heart failure, reducing their risk of worsening heart failure or death from cardiovascular causes by more than 25%.
The DAPA-HF trial which was funded by Astrazeneca and led by Prof McMurray, looked at 4,744 patients from 20 countries around the world. Researchers then measured the effectiveness of the drug against a placebo. Around half the patients enrolled in the trial did not have diabetes.
Researchers involved in the trial presented their data which showed that dapagliflozin reduced patients’ risk of heart failure worsening or cardiovascular death by 26%.
Professor John McMurray, said: “These are really once in a lifetime findings, that show that a commonly prescribed drug for diabetes can effectively be used to treat people with heart failure.”
He continued: “With dapagliflozin, we did the three things you want to do for the patient in the ideal world: make them feel better, keep them out of hospital and keep them alive. That’s why we’re so delighted with the results.”
You can read the full story from our University of Glasgow site
The results were not only published in New England Journal of Medicine https://www.nejm.org/doi/full/10.1056/NEJMoa1911303 but they made the headlines too.
Below is a list of the news coverage on the “remarkable” results:
First published: 10 October 2019